ABSI Collaboration

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

Published August 07, 2025 at 06:00 AM

BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall’s selection of a second target aimed at dermatological indications.

Related Questions

Are there any contingent or performance‑based clauses in the partnership that might trigger additional financial obligations? How will the expansion of the AI drug discovery collaboration affect Almirall's and Absci's upcoming earnings forecasts? How does this collaboration compare to similar AI‑driven drug discovery deals in the biotech sector? Could the announcement lead to a re‑rating of the companies by analysts, influencing their price targets? How might this expanded collaboration affect the competitive landscape for existing dermatology treatments? What potential regulatory hurdles could delay progress on the new dermatology target? Will the partnership generate any new licensing or milestone payments that could impact cash flow? What is the likely impact on the share volume and volatility for both Almirall (ALM) and Absci (ABSI) in the short term? What is the expected timeline for the second dermatology target to reach pre‑clinical or clinical milestones? What is the market's perception of AI integration in drug development for dermatology, and could this drive broader investor interest?